Drug discovery and development process are long, complex, and dependent on numerous factors. Machine learning can now help predict the physical and chemical properties of large molecules with improved efficiency and high accuracy. By leveraging AWS ML capabilities, companies like Bristol-Myers Squibb (BMS) have found new efficiencies to automate image classification process during protein crystallization. In this session, BMS and AWS Data Scientist share how they used AWS SageMaker image classification algorithm to achieve high levels of accuracy in classifying protein crystal images.
Presented by Geoffrey Kinnel, Lead, IT Business Partner, Drug Product Development, Bristol Myers Squibb
